A unique pediatric thoracic fibrosarcoma: Case report and successful therapeutic strategy
- PMID: 41045685
- PMCID: PMC12528867
- DOI: 10.1016/j.ijscr.2025.111999
A unique pediatric thoracic fibrosarcoma: Case report and successful therapeutic strategy
Abstract
Introduction and significance: Congenital Infantile Fibrosarcoma (CIFS) is an exceptionally rare pediatric malignancy, representing approximately 10 % of all soft tissue cancers in young children. Its clinical manifestations vary according to tumor location. When tumors occur in unusual anatomical sites, symptoms may be misleading and delay proper diagnosis and treatment.
Case presentation: We report an 11-month-old male with a month-long persistent dry cough and high fever unresponsive to antibiotics. Chest CT revealed a pleural mass with mild effusion. Thoracotomy achieved complete excision (R0). Histopathology showed low-grade fibrosarcoma; immunohistochemistry was positive for Vimentin and SMA, focally CD34, and negative for S100, Desmin, and Myogenin, with low Ki-67 (<3 %). ETV6-NTRK3 fusion testing was unavailable. The patient received six cycles of adjuvant VAC chemotherapy and tolerated treatment well, with only mild transient neutropenia.
Clinical discussion: Diagnosis depends on histopathological and immunohistochemical analysis, as CIFS mimics several other soft tissue sarcomas. Our review of medical literature found no prior cases of CIFS originating in the pleura, underlining the uniqueness of this case. Management followed a standard multidisciplinary approach consisting of complete surgical excision and adjuvant chemotherapy (VAC protocol). At 12-month follow-up, the patient remained recurrence-free.
Conclusion: Persistent pneumonia-like symptoms unresponsive to standard treatment in infants should prompt consideration of underlying malignancy. Early recognition and prompt management are essential for improving outcomes in such rare presentations.
Keywords: CaseReport-pediatric-fibrosarcoma; Congenital-infantile.
Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Conflict of interest statement The authors declare that they have no competing interests.
Figures
References
-
- Al-Ibraheemi A., Zhou Y., Rullo E., Alaggio R. What is new in fibroblastic/myofibroblastic tumors in children. Virchows Arch. Advance online publication. 2024 doi: 10.1007/s00428-024-03981-8. Nov 16. - DOI
-
- González-López J., Rubio-Martínez L.A., Atarés M., Amaya J.V., Huart M.C., Mayordomo-Aranda E., Giner F. Novel EVI5::BRAF Gene Fusion in Infantile Fibrosarcoma: A Case Report and Review of Literature. Int. J. Mol. Sci. 2025;26(3):1182. doi: 10.3390/ijms26031182. Published 29 Jan 2025. - DOI - PMC - PubMed
-
- Laetsch T.W., Voss S., Ludwig K., Hall D., Barkauskas D.A., Dubois S.G., Ronan J., Rudzinski E.R., Memken A., Robinson K., Sorger J., Reid J.M., Bhatla T., Crompton B.D., Church A.J., Fox E., Weigel B.J. Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion-Positive Solid Tumors (Children’s Oncology Group ADVL1823) J. Clin. Oncol. 2025 Apr;43(10):1188–1197. doi: 10.1200/JCO-24-01854. - DOI - PMC - PubMed
-
- Corral Sánchez M.D., Jiménez Carrascoso R., Rubio Aparicio P., Plaza López de Sabando D., Sastre Urgelles A., Pozo-Kreilinger J.J., López Gutiérrez J.C., Gómez Cervantes M., Ortiz Cruz E.J., Pérez-Martínez A. Therapeutic strategies and clinical evolution of patients with infantile fibrosarcoma: a unique paediatric case series. Clin. Transl. Oncol. 2023;25(11):3307–3311. doi: 10.1007/s12094-023-03175-9. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
